Michael Benzaquen

Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland

Michael Benzaquen, Luca Borradori, P. Berbis et al. · Journal of the American Academy of Dermatology · 2017 · 156 citations · Full text

Veterinary Medicine, Pharmacotherapy, Risk Factor Analysis +6

Development and accuracy of an artificial intelligence algorithm for acne grading from smartphone photographs

Sophie Seité, Amir Khammari, Michael Benzaquen et al. · Experimental Dermatology · 2019 · 77 citations · Full text

Computing, Computer Science, Dermatology +16

PPAR-γ regulates the effector function of human T helper 9 cells by promoting glycolysis

Nicole Bertschi, Oliver Steck, Fabian Luther et al. · Nature Communications · 2023 · 58 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Cutaneous and pulmonary dirofilariasis due to <i>Dirofilaria repens</i>

Michael Benzaquen, D. Brajon, Marion Delord et al. · British Journal of Dermatology · 2015 · 28 citations

Veterinary Medicine, Dermatology, Infectious Diseases +9

Clinical, biological and histological characteristics of bullous pemphigoid associated with anti‐PD‐1/PD‐L1 therapy: A national retrospective study

C. Juzot, V. Sibaud, F. Amatore et al. · Journal of the European Academy of Dermatology and Venereology · 2021 · 26 citations

Life Sciences, Pathobiology, Autoimmunity +8